No abstract available.
Leuprolide* ; Pityriasis Rosea* ; Pityriasis*

No abstract available.
Endometriosis ; Female ; Leuprolide* ; Pityriasis Rosea*

We report a case of atypical pityriasis rosea in a 24-year-old Malay man. He presented with an 11-month history of three recurrent and persistent episodes of pityriasis rosea associated with oral ulcers. The first episode lasted for one month and recurred within 14 days. The second episode lasted for three months and recurred within nine days. The third episode lasted for seven months. Although all three episodes were not preceded by any prodromal symptoms, a herald patch was noted on three different sites (the left iliac fossa, abdomen and chest) on each successive episode. Recurrent pityriasis rosea and its association with oral ulcers, although quite uncommon, have been reported in the literature. However, reports of multiple recurrences, with prolonged duration of each episode and very short remissions in between, have not been made. To the best of our knowledge, this is the first report of such unique presentation.
Adult ; Diagnosis, Differential ; Exanthema ; diagnosis ; pathology ; Humans ; Male ; Oral Ulcer ; complications ; diagnosis ; Pityriasis Rosea ; diagnosis ; pathology ; Recurrence ; Treatment Outcome

No abstract available.
Humans ; Interferon-gamma* ; Pityriasis Rosea*

Imatinib mesylate (Gleevec(TM), STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.
Benzamides ; Drug Eruptions ; Gastrointestinal Stromal Tumors ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Mesylates ; Piperazines ; Pityriasis ; Pityriasis Rosea ; Pyrimidines ; Imatinib Mesylate

BACKGROUND: Pityriasis rosea is an acute inflammatory dermatosis with an unproven etiology. The typical clinical feature consists of an initial, single herald patch followed by the development of smaller, disseminated, papulosquamous and ovoid macules. OBJECTIVE: The aim of this study was to evaluate the clinical manifestations of pityriasis rosea. METHODS: We examined a total of 101 patients with pityriasis rosea who visited the Department of Dermatology in Chung-Ang University Medical Center from March of 2005 to February of 2010. RESULTS: There were 1.53 times more women (61 patients) than men (40 patients) among the study subjects. The age of onset varied from 4 years to 71 years with a mean age of 28.7 years and 60% of the cases were 20 years to 39 years old. The percentage of seasonal variation was 34% in winter, 24% in summer, 22% in spring and 21% in autumn. A herald patch was found in 43% and the main predilection sites were the trunk and the thigh. Secondary eruptions could be classified into the macular type (67%), papular type (30%), urticarial type (2%) and purpuric type (1%). They appeared on the back, the chest, the abdomen, the upper arms, the thighs, the neck, the forearm, the lower legs, the face, the hands and the feet. The histopathological findings of all the types of lesions were focal parakeratosis, intraepidermal vesicles and papillary dermal edema. As compared to the macular type, hyperkeratosis, parakeratosis and exocytosis of lymphocytes were less commonly observed in the papular type. CONCLUSION: Most of the study results were compatible with those of other previous studies. However, the number of patients with papular type pityriasis rosea was currently increasing.
Abdomen ; Academic Medical Centers ; Age of Onset ; Arm ; Dermatology ; Edema ; Exocytosis ; Female ; Foot ; Forearm ; Hand ; Humans ; Leg ; Lymphocytes ; Male ; Neck ; Parakeratosis ; Pityriasis ; Pityriasis Rosea ; Seasons ; Skin Diseases ; Thigh ; Thorax

BACKGROUND: Pityriasis rosea is an acute inflammatory dermatosis with an unproven etiology. The typical clinical feature consists of an initial, single herald patch followed by the development of smaller, disseminated, papulosquamous and ovoid macules. OBJECTIVE: The aim of this study was to evaluate the clinical manifestations of pityriasis rosea. METHODS: We examined a total of 101 patients with pityriasis rosea who visited the Department of Dermatology in Chung-Ang University Medical Center from March of 2005 to February of 2010. RESULTS: There were 1.53 times more women (61 patients) than men (40 patients) among the study subjects. The age of onset varied from 4 years to 71 years with a mean age of 28.7 years and 60% of the cases were 20 years to 39 years old. The percentage of seasonal variation was 34% in winter, 24% in summer, 22% in spring and 21% in autumn. A herald patch was found in 43% and the main predilection sites were the trunk and the thigh. Secondary eruptions could be classified into the macular type (67%), papular type (30%), urticarial type (2%) and purpuric type (1%). They appeared on the back, the chest, the abdomen, the upper arms, the thighs, the neck, the forearm, the lower legs, the face, the hands and the feet. The histopathological findings of all the types of lesions were focal parakeratosis, intraepidermal vesicles and papillary dermal edema. As compared to the macular type, hyperkeratosis, parakeratosis and exocytosis of lymphocytes were less commonly observed in the papular type. CONCLUSION: Most of the study results were compatible with those of other previous studies. However, the number of patients with papular type pityriasis rosea was currently increasing.
Abdomen ; Academic Medical Centers ; Age of Onset ; Arm ; Dermatology ; Edema ; Exocytosis ; Female ; Foot ; Forearm ; Hand ; Humans ; Leg ; Lymphocytes ; Male ; Neck ; Parakeratosis ; Pityriasis ; Pityriasis Rosea ; Seasons ; Skin Diseases ; Thigh ; Thorax

Pityriasis rosea, first described by Gilbert in 1860, is a fairly common dermatosis. The exact cause of pityriasis rosea is not known. The earliest clinical finding of a typical case is a herald patch, which is usually on the trunk, and scaly and erythematous daughter macules, which is distributed along the skin cleavage line, such as the 'Christmas tree pattern'. This may be accompanied by Itching. Atypical cases of pityriasis rosea, such as palmoplantar, unilateral, vesicular and inverse forms, have also been reported. There is no difference between typical and atypical cases regarding the presence of a herald patch and/or symptoms. Differences between typical and atypical cases lie in the distribution of skin lesions and the characteristics of daughter macules. Hands and feet, including palms and soles, are rarely involved in pityriasis rosea. Moreover, there are no reported pathologic findings of pityriasis rosea of the palms and soles, even in atypical distributed pityriasis rosea case reports. Here, we report atypical case of pityriasis rosea with palmoplantar involvement with pathologic reports.
Foot ; Hand ; Nuclear Family ; Pityriasis ; Pityriasis Rosea ; Pruritus ; Skin ; Skin Diseases

Adalimumab is the first fully humanized monoclonal anti-tumor necrosis factor alpha (TNF-alpha) antibody. This drug has been shown to be of benefit in patients with inflammatory diseases in which TNF-alpha is involved, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. As the use of adalimumab is becoming more widespread, cutaneous side effects are being increasingly reported. Various dermatologic adverse events have been reported in the literature, including injection site reactions, psoriasis-like eruption and pityriasis rosea. Herein, we describe a case of GA associated with adalimumab treatment for adult-onset Still's disease, which has not been reported in Korea.
Antibodies, Monoclonal, Humanized ; Arthritis, Psoriatic ; Arthritis, Rheumatoid ; Crohn Disease ; Granuloma ; Granuloma Annulare ; Humans ; Korea ; Necrosis ; Pityriasis Rosea ; Spondylitis, Ankylosing ; Still's Disease, Adult-Onset ; Tumor Necrosis Factor-alpha ; Adalimumab

BACKGROUND: UVA1 phototherapy has recently demonstrated high levels of efficacy and tolerability for treating a variety of inflammatory and neoplastic skin diseases. OBJECTIVE: The purpose of the present study was to assess the clinical efficacy of UVA1 (340~400 nm) phototherapy for treating pityriasis rosea and to assess the course of the disease after treatment. METHODS: Fifteen patients with extensive pityriasis rosea were treated with low-dose UVA1 phototherapy (starting at 10~20 J/cm2 and then it was increased to 30 J/cm2). The treatments were given 2~3 times a week until complete clearance of lesions was achieved or until there was partial improvement without further amelioration, in spite of 5 additional treatments. The rate of clearing was monitored by estimating the pityriasis rosea severity (PRSS) score and the pruritus score. RESULTS: The extent of disease (PRSS) in all 15 patients lessened during the study (30.1+/-3.6 vs. 2.0+/-1.6, respectively, p<0.05). The overall reduction of the PRSS showed a significant improvement after the second or third treatment. The pruritus of 12 of 15 patients lessened during the treatment period, and it was unchanged in the remaining 3 patients. The mean previous duration of disease was 11.2+/-4.9 days and this did not interfere with the successful outcome of UVA1 phototherapy. CONCLUSION: This study shows that UVA1 phototherapy is a useful, well-tolerated treatment option for patients suffering from pityriasis rosea with extensive eruptions and considerable pruritus.
Humans ; Phototherapy ; Pityriasis ; Pityriasis Rosea ; Pruritus ; Skin ; Stress, Psychological